Table 2 Comparison of post-COVID-19 syndrome symptoms in rheumatic diseases patients
From: Assessment of symptoms of the post-COVID-19 syndrome in patients with different rheumatic diseases
Parameter mean ± SD or n (%) | RA n = 21 | SLE n = 17 | axSpA n = 11 | PsA n = 9 | Overlap n = 10 | P |
|---|---|---|---|---|---|---|
Cough | 2 (9.5) | 9 (52.9) | 5 (45.4) | 2 (22.2) | 4 (40) | 0.041 |
Dyspnea | 11 (52.3) | 11 (64.7) | 2 (18.18) | 2 (22.2) | 4 (40) | 0.081 |
Weakness | 6 (28.5) | 10 (58.8) | 0 (0) | 2 (22.2) | 5 (50) | 0.0151 |
Fatigue | 13 (61.9) | 16 (94.1) | 2 (18.2) | 8 (88.8) | 8 (80) | 0.00011 |
Attention problem | 11 (52.3) | 17 (100) | 1 (9.1) | 4 (44.4) | 6 (60) | 0.00011 |
Myalgia | 17 (80.9) | 17 (100) | 1 (9.1) | 7 (77.7) | 8 (80) | 0.00011 |
Headache | 1 (4.7) | 10 (58.8) | 0 (0) | 0 (0) | 4 (40) | 0.00011 |
Paraesthesia | 9 (42.8) | 8 (47.05) | 0 (0) | 1 (11.1) | 5 (50) | 0.0271 |
Anosmia | 0 (0) | 4 (23.5) | 0 (0) | 0 (0) | 2 (20) | 0.0391 |
Autoantibodies | ||||||
 ANA-IIF | 4 (20) | 15 (88.2) | 0 (0) | 2 (22.2) | 9 (9) |  |
 RF | 15 (71.4) | 2 (11.7) | 0 (0) | (0) | 4 (4) |  |
 Anti-CCP | 17 (81) | (0) | 0 (0) | 3 (33.3) | 2 (2) |  |
 Anti-dsDNA | 0 (0) | 13 (76.47) | 0 (0) | 0 (0) | 2 (2) |  |
FSS score | 32.1 ± 9.6 | 48.4 ± 9.7 | 19.5 ± 5.5 | 35.8 ± 10.1 | 37.9 ± 11.2 | 0.00012 |
SF-MPQ-2 | 19.1 ± 9.4 | 30.5 ± 4.8 | 9 ± 2.9 | 20.4 ± 9.2 | 27.1 ± 8.8 | 0.00012 |
HADS (anxiety) | 12.1 ± 3 | 15.2 ± 2.5 | 8.1 ± 1.4 | 12.4 ± 4.2 | 13.4 ± 2.1 | 0.00012 |
HADS(depression) | 12.1 ± 2.6 | 15.2 ± 2.5 | 8 ± 1.4 | 12.2 ± 2.8 | 13.7 ± 2.8 | 0.00012 |
MMSE score | 22.1 ± 3.2 | 17.9 ± 1.4 | 25.3 ± 1.6 | 22.3 ± 1.7 | 21 ± 2.4 | 0.00012 |
Disease activity | DAS28-CRP 4.1 ± 0.7 | SLEDAI 12.7 ± 6.8 | ASDAS 1.7 ± 0.4 | DAPSA 23.6 ± 7 |  | - |